Journal of the National Cancer Institute
Erythropoiesis-stimulating agents associated with higher risk of venous thromboembolism
Published in Blood Weekly, November 26th, 2009
Erythropoiesis-stimulating agents (i.e., erythropoietin and darbopoietin) stimulate red blood cell production and therefore were approved to reduce the number of blood transfusions required during chemotherapy; however, concerns about the risks of venous thromboembolism (the disease that includes deep vein thrombosis and pulmonary embolism) and mortality exist.
Dawn L. Hershman, M.D., of Columbia University Medical Center in New York, and colleagues...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
Source: Blood Weekly (2009-11-26)
More Articles from Blood Weekly
- Columbia University Medical Center
Drugs to treat anemia in cancer patients linked to thromboembolism - Aethlon Medical, Inc.
Aethlon Medical Appoints Douglas Taylor to Exosome Sciences Advisory Board - Aileron Therapeutics
Aileron Therapeutics Collaborators Publish In Vivo Research in Nature Showing Stapled Peptides Achieve the First Direct Inhibition of the Notch1 Transcription Factor Oncogene - Dialysis
Studies from A.B. Korkor et al have provided new data on dialysis - Gaucher Disease
New data from McGill University illuminate research in Gaucher disease - Gaucher Disease
Research by A.A.K.A. Razek and colleagues in Gaucher disease provides new insights - More from this issue of Blood Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
